Hints and tips:
Related Special Reports
...Under the agreement, Paris-based Sanofi would lead the sales push of Novavax’s Covid jab from next year in most countries and have the rights to combine the US biotech’s protein-based vaccine technology...
...The other big vaccine makers, including Sanofi and GSK, are now working on mRNA....
...Another said that the US drugmaker replaced the doses that had expired for free....
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...US district judge Robin Rosenberg in Florida on Tuesday dismissed thousands of lawsuits claiming that the drug Zantac causes cancer....
...Earlier on Monday, French pharmaceutical company Sanofi struck a deal to buy Type-1 diabetes treatment developer Provention Bio for $2.9bn, in a bid to bolster its drug pipeline after facing pressure from...
...Details of a draft deal reported by the FT suggest that BioNTech/Pfizer could supply as many as 70mn doses a year until 2026, leaving little room for Novavax, Moderna or Sanofi....
...Novavax’s Stanley Erck will be replaced by John C Jacobs, most recently chief executive at Harmony Biosciences, this month; CureVac’s Franz-Werner Haas will be succeeded by Alexander Zehnder, a Sanofi veteran...
...Another hit will come when the US patents on its top selling osteoporosis treatments Prolia and Xgeva expire in 2025....
...Horizon said last month that it was in takeover talks with three potential suitors, among them Johnson & Johnson and Sanofi....
...Banco Santander, BT Group, Centrica, CMC Markets, Co-operative Bank, CVS Group, Diageo, Enel, Hammerson, JCDecaux, L’Oréal, Leonardo, Nestlé, OMV, Orange, Relx, Rentokil Initial, Repsol, Royal Dutch Shell, Sanofi-Aventis...
...Horizon’s assets, which include treatments for chronic gout and neuromyelitis optica, a disease affecting the central nervous system, had also attracted interest from Johnson & Johnson and Sanofi....
...in Europe than in the US....
...But prices may be a lot higher in the US, which is moving from government purchases to a private market and where Moderna has said it could charge up to $100 per shot....
...The US drugmaker needs to refill its pipeline as it prepares for its mega blockbuster cancer drug Keytruda to lose patent protection by the end of the decade....
...In June, Sanofi and GSK reported promising results from trials of their Covid vaccine, which they said had proved effective against the Omicron strain of coronavirus....
...The US vaccine maker has raced ahead of competitors with this promising initial data....
...H1, Mastercard Q2, Merck & Co Q2, Nestlé H1, Nissan Motor Q1, Northrop Grumman Q2, OMV Q2, Orange H1, Panasonic Q1, Pfizer Q2, Relx H1, Rentokil Initial H1, Repsol Q2, Royal Dutch Shell Q2, Samsung Q2, Sanofi-Aventis...
...Stephen Hoge, Moderna’s president, told investors that the vaccine candidate, which elicited roughly the same immune response as Sanofi’s US market leader Fluzone, was just a “starting point”....
..., monthly motor vehicle sales, payrolls and unemployment figures Results: Aon Q4, Bristol-Myers Squibb Q4, Carlsberg FY, Intesa Sanpaolo FY, Regeneron Pharmaceuticals Q4, Sanofi-Aventis Q4, Sumitomo Q3,...
...“The US has moved to approve boosters,” he noted, “but for a population that falls short of everyone everywhere.”...
...In June, Sanofi expanded its partnership with Translate Bio, a US-based company that it has worked with since 2018 to explore mRNA vaccines for all infectious diseases....
...“As we move into the next couple of years there’s a whole wave of vaccines that are likely going to be approved — GSK, Sanofi, and a lot of other players,” Conover said, noting that Pfizer will struggle...
...Q2 Mediobanca Q2 Merck & Co Q2 National Express H1 Nestle H1 Northrop Grumman Q2 Orange H1 Panasonic Q1 Pinterest Q1 Rentokil H1 Repsol Q2 Royal Dutch Shell Q2 Saint-Gobain H1 Samsung Q2 Sanofi-Aventis...
...AstraZeneca pulled out of this line of research in 2016, followed by Sanofi and Novartis in 2018....
International Edition